Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

  1. Bellmunt, J.
  2. González-Larriba, J.L.
  3. Prior, C.
  4. Maroto, P.
  5. Carles, J.
  6. Castellano, D.
  7. Mellado, B.
  8. Gallardo, E.
  9. Perez-Gracia, J.L.
  10. Aguilar, G.
  11. Villanueva, X.
  12. Albanell, J.
  13. Calvo, A.
Revista:
Annals of Oncology

ISSN: 0923-7534,  1569-8041

Ano de publicación: 2011

Volume: 22

Número: 12

Páxinas: 2646-2653

Tipo: Artigo

DOI: 10.1093/ANNONC/MDR023 GOOGLE SCHOLAR lock_openAcceso aberto editor

Obxectivos de Desenvolvemento Sustentable

Fonte de datos: Scopus